Skip to main content

The Implications of Human Stem Cell Differentiation to Endothelial Cell Via Fluid Shear Stress in Cardiovascular Regenerative Medicine: A Review

Buy Article:

$68.00 + tax (Refund Policy)

Stem cell therapy heralds a new chapter in cardiovascular regenerative medicine. Cardiovascular implants are often used in both surgery and interventional cardiology. Cardiovascular stents are utilized in percutaneous coronary interventions (PCI), and are classified as either bare metal stents (BMS) or drug-eluting stents (DES). Although DES might decrease the risk of vascular restenosis, there are complications (e.g. thrombosis) associated with it as well. Many new and novel composite materials are increasingly being developed along the premise of mobilizing and attracting endogenous stem cells to home-in and differentiate into a confluent layer of endothelial cell around the vessel wall. One of the main forces acting on cells in a blood vessel wall is fluid shear stress. Fluid shear stress is vital in establishing the vasculature of the embryo, and different shear stress patterns have been both implicated in maintaining vascular physiology, and also associated with certain pathological conditions. Recent evidence suggests that via a plethora of mechanosensors and mechanotransduction signaling pathways, stem cells differentiate into endothelial cells when exposed to fluid shear stress. Here we review the current knowledge pertaining to the roles that mechanosensors and mechanotransducers play in stem cell differentiation into endothelial cells via fluid shear stress, and its implications for pharmacological applications and cardiovascular implants in the realm of regenerative medicine.





Keywords: -catenin signaling pathway; Bare metal stents; Cardiovascular; Caveolin; Cl- channel; Cytoskeleton & tensegrity model; ENaC; Epigenetics; FK-binding proteins (FKBPs); GPCR; Glycocalyx; HDAC7; HPB EPC; Human PDEC; Human PDMC; Integrin; JAK-STAT pathway; K+ channel; Kartagener syndrome; Laminar,15 d; Mechanotransduction; Neutropenia; Paclitaxel; Pharmacology; Primary cilia; Shear stress; Sirolimus; Stem cell; TRP; VEGF; Wnt5a; band-aid; ciliary dyskinesia; circulatory loop system (CLS); coronary valve replacements; drug-eluting stents; dynein; els (generic); endothelializa-tion potential; everolimus; growth factor (VEGF); hESC-derived EC; inhibitor of DNA; laminar fluid shear stress; mammalian target-of-rapamycin; matrix met-alloproteinase-1; nanocomposites; nitric oxide synthase (eNOS); percutaneous; plasminogen activator inhibitor-1; rapamycin; superoxide dismutase; vascular restenosis; zotarolimus

Document Type: Research Article

Publication date: 01 November 2010

More about this publication?
  • Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

    Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content